This inventor holds 2 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Exosomics S.p.a., Medica Corporation. Active years: 2024-2025.
Company Filing History:
Years Active: 2024-2025
Title: Antonio Chiesi: Innovator in Exosome Research
Introduction
Antonio Chiesi is a notable inventor based in Siena, Italy. He has made significant contributions to the field of exosome research, particularly in methods related to the capture and analysis of tumor-derived exosomes. With a total of 2 patents, his work has implications for cancer diagnostics and treatment.
Latest Patents
Chiesi's latest patents include innovative methods and kits for isolating CA-IX positive exosomes. These methods involve immunocapture with an anti CA-IX antibody, allowing for the quantification of tumor-related nucleic acid sequences from the isolated exosomes. Additionally, he has developed techniques for determining the presence of tumors in subjects in vitro. Another significant patent focuses on the use of hollow fibers to obtain blood or blood derivatives that are impoverished from blood cells and platelets, specifically targeting extracellular vesicles like exosomes. This method utilizes hollow fibers with a porosity above 20 nm, particularly polyethersulfone hollow fibers, to effectively impoverish blood and blood derivatives from these vesicles.
Career Highlights
Throughout his career, Antonio Chiesi has worked with prominent companies in the biotechnology sector, including Medica S.p.a. and Exosomics S.p.a. His expertise in exosome research has positioned him as a key figure in the development of diagnostic tools for cancer.
Collaborations
Chiesi has collaborated with notable professionals in his field, including Natasa Zarovni and Davide Zocco. These collaborations have further enhanced the impact of his research and innovations.
Conclusion
Antonio Chiesi's contributions to exosome research and his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer diagnostics and treatment methodologies.